Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors

Inactive Publication Date: 2006-01-12
DAVIS HARRY R +3
View PDF99 Cites 9 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0006] Despite the current approaches for the treatment or prevention of obesity, there remains a need in the art for improved compositions and treatments for obesity.
[0007] One embodiment of the present invention provides a composition comprising (a) at least one obesity control medication; and (b) at least one sterol absorption inhibitor and/or at least one 5α-stanol absorption inhibitor or a pharmaceutically acceptable salt thereof or a solvate thereof.
[0008] Therapeutic combinations also are provided comprising: (a) a first amount of at least one obesity control medication; and (b) a second amount of at least one sterol absorption inhibitor and/or at least one 5α-stanol absorption inhibitor or a pharmaceutically acceptable salt thereof or a solvate thereof, wherein the first amount and the s

Problems solved by technology

Such definitions of obesity, however, are not a measure of body composition and different people may have higher or lower levels of body fat or muscle mass for their height.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
  • Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
  • Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors

Examples

Experimental program
Comparison scheme
Effect test

example

Preparation of Compound of Formula (II)

[0409] Step 1): To a solution of (S)-4-phenyl-2-oxazolidinone (41 g, 0.25 mol) in CH2Cl2 (200 ml), was added 4-dimethylaminopyridine (2.5 g, 0.02 mol) and triethylamine (84.7 ml, 0.61 mol) and the reaction mixture was cooled to 0° C. Methyl-4-(chloroformyl)butyrate (50 g, 0.3 mol) was added as a solution in CH2Cl2 (375 ml) dropwise over 1 h, and the reaction was allowed to warm to 22° C. After 17 h, water and H2SO4 (2N, 100 ml), was added the layers were separated, and the organic layer was washed sequentially with NaOH (10%), NaCl (sat'd) and water. The organic layer was dried over MgSO4 and concentrated to obtain a semicrystalline product.

[0410] Step 2): To a solution of TiCl4 (18.2 ml, 0.165 mol) in CH2Cl2 (600 ml) at 0° C., was added titanium isopropoxide (16.5 ml, 0.055 mol). After 15 min, the product of Step 1 (49.0 g, 0.17 mol) was added as a solution in CH2Cl2 (100 ml). After 5 min., diisopropylethylamine (DIPEA) (65.2 ml, 0.37 mol) w...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Massaaaaaaaaaa
Massaaaaaaaaaa
Concentrationaaaaaaaaaa
Login to View More

Abstract

The present invention provides methods for the treatment of obesity using sterol or 5α-stanol absorption inhibitors and compositions and therapeutic combinations including sterol or 5α-stanol absorption inhibitors and at least one obesity control medication.

Description

CROSS-REFERENCE TO RELATED APPLICATION [0001] This application claims the benefit of priority from U.S. Provisional Patent Application Ser. No. 60 / 323,840, filed Sep. 21, 2001, and is a continuation-in-part of U.S. patent application Ser. No. 10 / 166,942, filed Jun. 11, 2002, each incorporated herein by reference.FIELD OF THE INVENTION [0002] The present invention relates to compositions and therapeutic combinations for treating obesity in a subject comprising the administration of sterol and / or 5α-stanol absorption inhibitor(s) or combinations with obesity control medications. BACKGROUND OF THE INVENTION [0003] Obesity is one of the most common medical problems in the United States and other developed countries and a risk factor for other illnesses, such as hypertension, diabetes, degenerative arthritis and myocardial infarction. Weight loss medications may be appropriate for use in selected patients who are obese or who are overweight with co-morbid conditions. [0004] One measure f...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/7052A61K31/397A61K45/06
CPCA61K31/397A61K31/70A61K31/7052A61K45/06C07H15/26A61K2300/00
InventorDAVIS, HARRY R.RESS, RUDYARD J.STRONY, JOHN T.VELTRI, ENRICO P.
OwnerDAVIS HARRY R